A1 Beta-casein-free Milk in Milk-intolerant Participants
Launched by A2 MILK COMPANY LTD. · Jan 1, 2025
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female participants aged 18 to 68 years
- • Irregularly consumed milk
- • Had self-reported mild-to-moderate digestive discomfort after milk consumption
- • Had normal electrocardiograms and blood pressure during quiet respiration
- Exclusion Criteria:
- • Known allergies to dairy products
- • Severe milk intolerance
- • A history of faecal impaction
- • Having suffered from GI disorders (e.g., irritable bowel syndrome, colitis, ulcerative colitis, or coeliac disease)
- • Currently being administered drugs for cardiovascular or metabolic disease
- • Trying to lose weight by following a diet or exercise regimen
- • Took any appetite or weight loss drugs for the previous three months
About A2 Milk Company Ltd.
a2 Milk Company Ltd. is a leading dairy nutrition company dedicated to providing high-quality products that focus on the unique benefits of A2 protein. Based in New Zealand and operating globally, the company specializes in milk and dairy products that are free from the A1 beta-casein protein, which some studies suggest may be linked to digestive discomfort. Committed to scientific research and innovation, a2 Milk Company Ltd. actively sponsors clinical trials to explore the health implications of A2 protein consumption, reinforcing its mission to enhance the wellbeing of consumers through superior dairy nutrition.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baton Rouge, Louisiana, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported